DIGITAL SPY
DIGITAL
spy
www.qosina.com EXPANDED PRODUCT LINE FOR SINGLE-USE BIOPROCESS COMMUNITY
PARTNERSHIP UPDATE
www.fosterpolymers.com www.drakemedicalplastics.com
Foster and Drake Medical Plastics create one-stop shop Foster Corp., a provider of polymer solutions for medical devices, has signed an exclusive sales agreement with Drake Medical Plastics, a converter of highperformance polymers into stock shapes and precision parts. The agreement streamlines their services to customers in the medical device marketplace globally, and creates a one-stop shop for high performance polymers in the form of machinable shapes. Based in Cypress, Texas, Drake Medical Plastics provides ‘resin-to-shape’ polymer conversion into rod, plate, and tube for machined components for the medical and
PRODUCT UPDATE
life science industries. Stock shapes provide customers with a quick and economical route for prototypes and scaling up to commercial manufacturing. Depending on volume, machined parts can also be a flexible platform for production parts with little to no capital investment. Currently, Foster provides highly engineered materials and compounds to be used in specialty medical and life sciences applications. With this collaboration, medical compounds including highly filled materials will be available in machinable shapes made from Foster’s full range of polymer compounds.
Global supplier of OEM single-use components to the medical and pharmaceutical industries Qosina has extended its product portfolio, developed specifically for the needs of the single-use bioprocess industry. The company now offers a comprehensive selection of components for the design, development and manufacture of single-use systems. Scott Herskovitz, Qosina President and CEO, said: “Our experience serving the needs of regulated customers positions us well to expand our products and services
COMPANY UPDATE
www.siigroup.com
SI GROUP INVESTS TO EXPAND THE US CHEMICAL MARKET Performance additives company SI Group has said it plans to invest more than $50 million across three manufacturing sites in North America to install globally competitive main antioxidant capacity to increase its supply for this important and growing market segment. This investment will expand the US chemical market, with a focus on supplying strategically located, critical raw materials to key partners in the region. With SI Group’s current extensive antioxidant manufacturing footprint in the US and backward integration, this planned expansion will increase its security of supply by offering a fully integrated portfolio of phenolic antioxidants in the US. The new capacity is anticipated to come online in the second half of
6
for the single-use bioprocess community. We have leveraged this experience and our extensive supply chain to provide a muchneeded resource for bioprocess, vaccine production, and cell and gene therapy.”
WWW.MEDICALPLASTICSNEWS.COM
2022. These projects are expected to create short-term construction jobs, followed by permanent manufacturing jobs once construction is complete. With projected growth in the polyolefins market in the US, the expansions will enable SI Group to increase its domestic supply to match growing demand, and further strengthen its position as a key partner to its customers.
